Analysts Offer Predictions for Nanobiotix FY2027 Earnings

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) – Investment analysts at HC Wainwright decreased their FY2027 earnings per share (EPS) estimates for Nanobiotix in a report released on Monday, March 30th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.37) for the year, down from their prior forecast of ($0.32). The consensus estimate for Nanobiotix’s current full-year earnings is ($1.18) per share. HC Wainwright also issued estimates for Nanobiotix’s FY2029 earnings at $1.21 EPS.

Nanobiotix (NASDAQ:NBTX) last posted its quarterly earnings results on Sunday, February 15th. The company reported ($0.23) EPS for the quarter. The firm had revenue of $3.42 million during the quarter.

A number of other equities research analysts also recently issued reports on the company. TD Cowen reiterated a “buy” rating on shares of Nanobiotix in a research report on Thursday, March 12th. Guggenheim increased their price objective on Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, April 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research report on Thursday, January 22nd. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Nanobiotix presently has a consensus rating of “Moderate Buy” and an average target price of $25.00.

Nanobiotix Stock Down 8.0%

Nanobiotix stock opened at $30.14 on Tuesday. Nanobiotix has a one year low of $2.99 and a one year high of $41.89. The business has a fifty day moving average price of $28.68 and a 200-day moving average price of $23.87.

Institutional Investors Weigh In On Nanobiotix

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Millennium Management LLC purchased a new stake in shares of Nanobiotix in the fourth quarter worth $390,000. Royal Bank of Canada raised its position in Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after purchasing an additional 2,500 shares in the last quarter. Marshall Wace LLP purchased a new stake in Nanobiotix during the fourth quarter valued at about $220,000. Finally, Optiver Holding B.V. purchased a new stake in Nanobiotix during the third quarter valued at about $101,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.